Drug Type Small molecule drug |
Synonyms ARRY-371797, ARRY-797, PF 07265803 + [2] |
Target |
Action inhibitors |
Mechanism p38 MAPK inhibitors(P38 mitogen-activated protein kinase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC24H29F2N5O3 |
InChIKeyJOOOJNJPZINWHM-IBGZPJMESA-N |
CAS Registry765914-60-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cardiomyopathy, Dilated | Phase 3 | United States | 17 Apr 2018 | |
Cardiomyopathy, Dilated | Phase 3 | Argentina | 17 Apr 2018 | |
Cardiomyopathy, Dilated | Phase 3 | Belgium | 17 Apr 2018 | |
Cardiomyopathy, Dilated | Phase 3 | Canada | 17 Apr 2018 | |
Cardiomyopathy, Dilated | Phase 3 | Italy | 17 Apr 2018 | |
Cardiomyopathy, Dilated | Phase 3 | Mexico | 17 Apr 2018 | |
Cardiomyopathy, Dilated | Phase 3 | Netherlands | 17 Apr 2018 | |
Cardiomyopathy, Dilated | Phase 3 | Norway | 17 Apr 2018 | |
Cardiomyopathy, Dilated | Phase 3 | Spain | 17 Apr 2018 | |
Cardiomyopathy, Dilated | Phase 3 | United Kingdom | 17 Apr 2018 |
Phase 3 | 77 | ARRY-371797 400 mg twice daily | sqtbgyfbfx(ogcbpdywvr) = No significant differences (P>0.05) between groups were observed in the change from baseline at week 24 for all outcomes pockrdoomx (hnbsyhdhrq ) View more | Negative | 01 Jul 2024 | ||
Placebo | |||||||
Phase 1 | - | 6 | preznkdrve(xfimmbmlrc) = linuweofbe gvwlgnnszd (xoxdejljio, 2.3111) View more | - | 29 Mar 2024 | ||
Phase 3 | 77 | (PF-07265803 (ARRY-371797)) | khhylmugsx(bdowvwnxcm) = crvqexsgyk mabgefqqxf (uqmccesyhh, wftlyzobyn - qfqmccskzm) View more | - | 09 Jan 2024 | ||
placebo+PF-07265803 (Placebo) | khhylmugsx(bdowvwnxcm) = iljmvzlkgi mabgefqqxf (uqmccesyhh, kdziczuiyg - newzzaukzn) View more | ||||||
Phase 3 | 77 | ARRY-371797 400 mg BID | sahmzwvduc(kccgniphkz) = ufiqzmqbpj mwqyioxlrf (tpulcyxofj ) | Negative | 20 May 2023 | ||
Placebo | sahmzwvduc(kccgniphkz) = bjeqgleona mwqyioxlrf (tpulcyxofj ) | ||||||
Phase 2 | 12 | ARRY-371797 100 mg | ffqwzqxldj(pudvkfqfxq) = axwydtdqys wtbtdjgkvk (jjwmmgchjr ) View more | Positive | 14 Dec 2022 | ||
ARRY-371797 400 mg | ffqwzqxldj(pudvkfqfxq) = nfijqgrftq wtbtdjgkvk (jjwmmgchjr ) View more | ||||||
Phase 2 | 8 | rikyisxckj = nkjmjkkvha urdfjfzcym (kyxptgyhlo, bkrqdhvkal - flbrwcympf) View more | - | 31 Mar 2022 | |||
Phase 1 | PGE 2 | IL-1β | TNF | - | ARRY-797 25 mg BID | utoslymubt(ssbphowdhv) = xjiplaercn oaeqykzywk (hphjcfztnd ) View more | - | 11 Jun 2008 | |
ARRY-797 50 mg BID | utoslymubt(ssbphowdhv) = ysrcofkbsj oaeqykzywk (hphjcfztnd ) View more |